AbbVie Inc. (ABBV)

81.59
0.71 0.88
NYSE : Health Technology
Prev Close 80.88
Open 80.51
Day Low/High 79.88 / 81.75
52 Wk Low/High 75.62 / 107.24
Volume 4.22M
Avg Volume 5.70M
Exchange NYSE
Shares Outstanding 1.48B
Market Cap 117.47B
EPS 3.70
P/E Ratio 22.30
Div & Yield 4.28 (5.11%)
Miles White of Abbott Labs: Cramer's Top Takeaways

Miles White of Abbott Labs: Cramer's Top Takeaways

Jim Cramer spotlights Abbott Laboratories CEO Miles White for his value-creating success.

Fundamentals Drive This Rally: Cramer's 'Mad Money' Recap (Thursday 11/16/17)

Fundamentals Drive This Rally: Cramer's 'Mad Money' Recap (Thursday 11/16/17)

Jim Cramer says don't be too quick to ascribe today's gains just to tax reform. This rally was roaring well before that. Instead, credit Cisco and Wal-Mart Stores.

FDA Approves AstraZeneca's Blood Cancer Drug

FDA Approves AstraZeneca's Blood Cancer Drug

With newly approved Calquence in hand, AstraZenca is set to compete against J&J-AbbVie's Inbruvica first on mantle cell lymphoma but down the road the challenge could be on more common blood cancers.

Allergan: How to Deal with an Emotional Position Unemotionally

When the market is completely against a stock, it is important to go back through the numbers and figure out what the company is worth.

Washington Uncertainty and a Healthcare Selloff Send Stocks Lower

Washington Uncertainty and a Healthcare Selloff Send Stocks Lower

Uncertainty in Washington, D.C., a healthcare sector in selloff mode and a big deals day on Wall Street sent U.S. equities lower to begin the week.

Stocks Burrow Further Into the Red on Logistics of Tax Cut Plan

Stocks Burrow Further Into the Red on Logistics of Tax Cut Plan

Stocks dig further into the red on Monday, Oct. 30, as investors weigh how a proposed phase-in corporate tax rate cut might impact U.S. companies.

Merck Weighs on Dow but Apple and Tech Rally Give Lift to Nasdaq

Merck Weighs on Dow but Apple and Tech Rally Give Lift to Nasdaq

Stocks are mixed on Monday as Mueller's Russia investigation takes its first concrete steps.

Stop Worrying About Valuations After Amazon, Alphabet and Microsoft's Earnings

Stop Worrying About Valuations After Amazon, Alphabet and Microsoft's Earnings

The revenue and profit gains from some of the biggest technology companies like Amazon AMZN, Alphabet GOOGL and Microsoft MSFT show that valuations aren't so stretched.

Google, Amazon, Aetna and Exxon - 5 Things You Must Know Before the Market Opens

Google, Amazon, Aetna and Exxon - 5 Things You Must Know Before the Market Opens

U.S. stock futures are rising on Friday, and the tech-heavy Nasdaq index is poised for sharp opening gains after Amazon.com, Alphabet, Microsoft and Intel issue powerful earnings reports.

There Is Sound Fundamental Reasoning Behind the Positivity: Market Recon

There Is Sound Fundamental Reasoning Behind the Positivity: Market Recon

The ECB's super dovish message was good for the markets.

Alphabet, Amazon and Expedia: This Is What You Must Know on Friday

Alphabet, Amazon and Expedia: This Is What You Must Know on Friday

U.S. futures point a higher open following earnings beats from Amazon, Alphabet and Microsoft after the bell on Thursday.

Futures and Dollar Rise as Trump Narrows Down Pool for Next Fed Chair

Futures and Dollar Rise as Trump Narrows Down Pool for Next Fed Chair

A decision should be made 'in the coming days.'

Third-Quarter U.S. Economic Growth to Reveal Hurricane Damage in Week Ahead

Third-Quarter U.S. Economic Growth to Reveal Hurricane Damage in Week Ahead

A string of severe hurricanes that swept across the south and southeastern portions of the U.S. and Puerto Rico toward the end of the third quarter could put a big dent in economic growth.

Get Ready for an Earnings Onslaught: Cramer's 'Mad Money' Recap (Friday 10/20/17)

Get Ready for an Earnings Onslaught: Cramer's 'Mad Money' Recap (Friday 10/20/17)

Jim Cramer's game plan is jam-packed for next week; this is the heart of earnings season.

UnitedHealth and a Bipartisan Healthcare Deal Send Dow, S&P 500 to Records

UnitedHealth and a Bipartisan Healthcare Deal Send Dow, S&P 500 to Records

A flood of earnings from the likes of UnitedHealth, Johnson & Johnson and Goldman Sachs keeps investors occupied on Tuesday.

Healthcare Drives Small Gains for Dow While Rest of Market Slips

Healthcare Drives Small Gains for Dow While Rest of Market Slips

A flood of earnings from the likes of UnitedHealth, Johnson & Johnson and Goldman Sachs keeps investors occupied on Tuesday.

UnitedHealth and Johnson & Johnson Lead Bruised Healthcare Sector to Gains

UnitedHealth and Johnson & Johnson Lead Bruised Healthcare Sector to Gains

Earnings beats from UnitedHealth Group Inc. and Johnson & Johnson led the healthcare sector to recover from a days-long presidential beating.

Las Vegas Shooting Holds Headlines While Stocks Jump to New Records

Las Vegas Shooting Holds Headlines While Stocks Jump to New Records

Stocks look past the worst mass shooting in U.S. history on Monday, Oct. 2, to trade at new records.

Stocks Trade at Records Again Even as Las Vegas Shooting Death Toll Rises

Stocks Trade at Records Again Even as Las Vegas Shooting Death Toll Rises

Stocks look past the worst gun shooting in U.S. history on Monday, Oct. 2, to trade at new records.

Stocks at Records as U.S. Manufacturing Conditions Improve

Stocks at Records as U.S. Manufacturing Conditions Improve

Stocks begin the new month and quarter with gains on Monday, Oct. 2, as manufacturing conditions hold in expansion territory for another month.

AbbVie And Bristol-Myers Squibb Announce Clinical Research Collaboration To Evaluate A Therapeutic Regimen In Advanced Solid Tumors

AbbVie And Bristol-Myers Squibb Announce Clinical Research Collaboration To Evaluate A Therapeutic Regimen In Advanced Solid Tumors

AbbVie (NYSE: ABBV) and Bristol-Myers Squibb Company (NYSE: BMY) today announced a clinical trial collaboration to evaluate the combination of AbbVie's investigational antibody drug conjugate ABBV-399 and...

Arconic, Idexx Laboratories, AbbVie: 'Mad Money' Lightning Round

Arconic, Idexx Laboratories, AbbVie: 'Mad Money' Lightning Round

Jim Cramer is bullish on Arconic, Idexx Laboratories, AbbVie. He's bearish on Fitbit, Qualcomm and Walgreens.

Don't Get Shaken Out of Good Stocks: Cramer's 'Mad Money' Recap (Wed 9/13/17)

Don't Get Shaken Out of Good Stocks: Cramer's 'Mad Money' Recap (Wed 9/13/17)

Don't be distracted and start buying high and selling low, says Jim Cramer. A good example? Don't trade Apple, own it.

AbbVie Is Likely to Correct: Book Some Profits

AbbVie Is Likely to Correct: Book Some Profits

ABBV has gone 'vertical' on the daily chart.

AbbVie Becomes #164 Most Shorted S&P 500 Component, Replacing Moody's Corp.

AbbVie Becomes #164 Most Shorted S&P 500 Component, Replacing Moody's Corp.

The most recent short interest data has been released for the 08/15/2017 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the S&P 500 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

5 of the Most Popular Stocks Owned by Wall Street's Elite, Revealed

5 of the Most Popular Stocks Owned by Wall Street's Elite, Revealed

Hedge fund managers are out with their top stock picks. So who made the list?

What SOX Says About Oversold Rallies

Expect the market to come down again.

Regeneron, BioMarin, AbbVie Could Explode 20% or More -- Analyst

Regeneron, BioMarin, AbbVie Could Explode 20% or More -- Analyst

Evercore ISI analyst Josh Schimmer is bullish on biotech.

Activision Blizzard, EPR Properties, AbbVie: 'Mad Money' Lightning Round

Activision Blizzard, EPR Properties, AbbVie: 'Mad Money' Lightning Round

Jim Cramer is bullish on EPR Properties, Activision Blizzard, AbbVie, and ON Semiconductor.

How Much Cash Do You Have on You?: Cramer's 'Mad Money' Recap (Monday 8/14/17)

How Much Cash Do You Have on You?: Cramer's 'Mad Money' Recap (Monday 8/14/17)

Cramer says this is not the end of the selloff. That's why you should be mentally and financially ready for panic moves -- and opportunities.

TheStreet Quant Rating: B- (Buy)